Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment

Jonathan Soverow, Salvador Hernandez, Daniel Sanchez, Colin Forsyth, Carmen A. Flores, Gracia Viana, and Sheba Meymandi

Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, Sylmar, California

Background. The objective of the study was to better understand the impact of antitrypanosomal treatment on the evolution of Chagas-related, prognostically important electrocardiogram (ECG) abnormalities.

Methods. Initial and posttreatment ECGs were obtained in a prospective cohort of Chagas patients treated with nifurtimox or benznidazole and compared to an untreated cohort. Electrocardiogram disease progression was compared in those with and without baseline abnormalities pre- and posttherapy.

Results. Fifty-nine patients were recruited in the treatment arm and followed for an average of 3.9 years. There were no differences between ECG groups with regards to follow-up, age, baseline ejection fraction, or therapy. In the treated cohort, 0 of 30 patients with normal ECGs developed an abnormal ECG compared with 7 of 29 patients with baseline ECG abnormalities who developed new ECG abnormalities (P = .005). In an untreated cohort of 30 patients, 3 of 7 with normal ECGs developed an abnormality compared with 14 of 23 patients with baseline abnormalities (P = .67). Untreated patients had a higher likelihood of developing new ECG abnormalities (56.7% vs 11.9%, P < .001) despite shorter follow-up, and in a multivariate analysis adjusting for baseline EKG status across both treated and untreated cohorts, treated patients were still less likely to have progression of their EKG disease (odds ratio = 0.13, P < .001). The corrected QT (QTc) interval was not significantly affected by either study medication (415 vs 421 ms, initial vs posttreatment QTc = P = .06).

Conclusions. Over an average follow-up of 3.9 years, treated patients with normal baseline ECGs did not have significant changes during a course of treatment; however, those with baseline abnormal ECGs had significant progression of their conduction system disease despite treatment, and those without treatment also experienced a progression of ECG disease. These preliminary results suggest that Chagas patients with normal ejection fraction and normal ECG may benefit the most from antitrypanosomal treatment.

Keywords. Chagas disease; chagas cardiomyopathy; electrocardiogram.

Chagas disease (CD) is a vector-borne illness arising from infection with the protozoan Trypanosoma cruzi, and it affects 6–7 million people worldwide, including an estimated 300,000 in the United States [1, 2]. Of those infected, 30%–40% progress from an indeterminate, asymptomatic form of serologic positivity to clinically expressed disease, including a cardiomyopathy marked by patchy fibrosis, systolic and diastolic dysfunction, apical aneurysm, thromboembolism, cardiogenic, microvascular damage, and both tachyarrhythmias and bradyarrhythmias [3–5]. A recent systematic review determined a prevalence of ECG abnormalities of 40.1% in people with CD from endemic regions, compared with 24% in the general population without CD. Right bundle branch block (RBBB) (odds ratio [OR] = 4.6), left anterior fascicular block (LAFB) (OR = 1.6), and combined RBBB/LAFB (OR = 3.34) were all significantly more likely in people with CD [6]. Moreover, ECG change is a potential harbinger of progression to more severe cardiomyopathy [7, 8]. Research suggests that antitrypanosomal treatment does not extend lifespan or improve heart function in those patients who have progressed to heart failure [9], but antiparasitic treatment before this stage may be beneficial [3, 10–12], because parasite load appears to correlate with the development of Chagas cardiomyopathy (CC) [13, 14]. Using characteristic ECG changes as a marker of early CD, we analyzed the largest single cohort of treated CD patients with normal heart function in the United States; the objective was to determine whether antitrypanosomal treatment altered the course of Chagas-related ECG changes over time in patients with and without baseline ECG abnormalities.
Electrocardiogram and echocardiography were performed at baseline (before treatment) and at the conclusion of therapy, with the final ECG conducted on the day of treatment discontinuation. Electrocardiograms were reviewed by a board-certified cardiologist blinded to treatment assignment, outcome, and LVEF. An “abnormal ECG” was defined as any ECG finding (eg, including sinus bradycardia <50 beats per minute or axis deviation) other than normal sinus rhythm with a normal axis. Electrocardiogram disease progression was further defined based on a development possibly attributable to CD: (1) new bundle branch block; (2) change in underlying rhythm; (3) shift in QRS axis; or (4) development of frequent premature ventricular complexes (PVCs)—defined as >1 PVC during a 10-second period. These 4 parameters were chosen given their prior associations with CD and represent a more conservative and specific subset of ECG findings than used in other studies of CD and ECG [17–19]. The corrected QT (QTc) was calculated by measuring the longest QT on the 12-lead ECG and dividing that value by the square root of the preceding R-R interval (Bazett’s formula). Left ventricular ejection fraction was calculated from transthoracic echocardiography using the biplane Simpson’s method of disks [20].

Baseline covariates were presented as mean ± standard deviation and compared using the Student t test or Fisher’s exact test. Electrocardiogram disease progression was compared in those with and without baseline ECG abnormalities pre- and posttherapy using Fisher’s exact test. The association of LVEF and baseline ECG abnormalities was assessed using Pearson’s correlation. Changes to a patient’s baseline QTc interval were compared based on treatment status or baseline ECG using a paired t test. A 2-tailed alpha <.05 was considered significant. All analyses were performed using STATA, version 14.1 (StataCorp, College Station, TX).

RESULTS
Fifty-nine patients from the treated cohort and 30 patients from the untreated cohort were included. Eighteen patients underwent treatment with benznidazole and 41 with nifurtimox. Three patients crossed over from nifurtimox to benznidazole and 1 patient crossed from benznidazole to nifurtimox due to adverse reactions. Five patients did not complete a full course of therapy with either drug. Patients were followed for an average of 3.9 years, and there were no differences between the 2 treatment groups with regards to length of follow-up, age, or drug used (Table 1). The untreated cohort was significantly older and had significantly lower ejection fraction (EF) at baseline compared with the treated cohort. Approximately half of the treated cohort (29 of 59) had ECG abnormalities at baseline. The most common baseline ECG abnormalities were sinus bradycardia (15), RBBB (5), and LAFB (4) (Table 2).

In the treatment cohort, 0 of 30 patients with normal ECGs developed an abnormal ECG during the study period compared with 7 of 29 patients with baseline ECG findings who developed new ECG abnormalities (P = .005) (Figure 1). No patients with
baseline ECG abnormalities regressed to a normal ECG, and there was no correlation between treatment discontinuation/ crossover and the development of ECG findings. Of those who developed new ECG changes, 3 developed new-onset bradycardia, 2 developed RBBB, and 2 developed PVCs.

In the untreated cohort, 3 of 7 with normal ECGs developed an abnormal ECG compared with 14 of 23 patients with baseline ECG abnormalities ($P = .67$). Of those who developed new ECG changes, 9 developed an indication for a pacemaker, 2 developed atrial fibrillation, 2 developed PVCs, and 1 developed LAFB. Overall, untreated patients had a higher likelihood of developing ECG abnormalities compared with their treated counterparts (56.7% vs 11.9%, $P < .001$) despite a significantly shorter follow-up period (26 vs 46 months, $P < .001$). In a multivariate analysis adjusting for baseline EKG status, treated patients were less likely have progression of their EKG disease ($OR = 0.13$, $P < .001$).

Treated subjects had normal mean baseline QTc intervals (414 ± 31 ms) that did not change significantly over the course of treatment with either medication (posttreatment, 420 ± 25 ms; $P = .06$). Ejection fraction was also normal at baseline in the treated cohort (mean 56% ± 2%) without significant change during treatment course ($P = .50$), as were mean baseline and posttreatment heart rates. There was no significant association between LVEF and baseline ECG abnormalities ($P = .98$) in the treated cohort. The average EF was lower in the untreated cohort (34% ± 14%), but again this was not statistically associated with baseline ECG abnormalities ($P = .77$).

**DISCUSSION**

In the largest single-center US cohort of treated CD patients, those with baseline ECG abnormalities developed new ECG changes despite antityrpanosomal therapy, whereas those without baseline ECG changes remained normal over the same time frame. Untreated patients had progression of their ECG disease regardless of baseline ECG status and at a significantly higher rate compared with treated patients, although there were significant important differences at baseline, including advanced age and deteriorated EF. In addition, neither nifurtimox nor benznidazole caused significant QTc prolongation compared with baseline or beyond the normal range. Although these results should be considered preliminary, our study suggests that baseline ECG changes in CD may be a harbinger of extensive disease before the onset of echocardiographic systolic failure, consistent with prior studies showing that ECG abnormalities tend

---

**Table 1. Baseline Characteristics**

| Treated Cohort | Normal Baseline ECG (n = 30) | Abnormal Baseline ECG (n = 29) | $P$ Value |
|----------------|-----------------------------|--------------------------------|-----------|
| Age (mean, years) | 41                          | 43                             | .47       |
| Nifurtimox treatment | 17                          | 17                             |           |
| Benznidazole treatment | 13                          | 12                             |           |
| Treatment duration (days) | 115 ± 29                   | 92 ± 9                         | .47       |
| ECG follow-up (months) | 45 ± 5                     | 48 ± 5                         | .71       |
| Baseline LVEF | 59% ± 2%                    | 56% ± 1%                       | .27       |
| LVEF at study conclusion | 57% ± 1%                   | 56% ± 1%                       | .46       |

| Untreated Cohort | Normal Baseline ECG (n = 7) | Abnormal Baseline ECG (n = 23) | $P$ Value |
|-----------------|-----------------------------|--------------------------------|-----------|
| Age (mean, years) | 53                         | 57                             | .56       |
| ECG follow-up (months) | 34 ± 5                    | 24 ± 4                         | .15       |
| Baseline LVEF | 35% ± 6%                    | 33% ± 3%                       | .77       |
| Baseline heart rate (bpm) | 70 ± 7                    | 74 ± 3                        | .59       |

| Combined groups | Treated (n = 59) | Untreated (n = 30) | $P$ Value |
|-----------------|-----------------|-------------------|-----------|
| Age (mean, years) | 42              | 56                 | <.001     |
| ECG follow-up (months) | 46 ± 3       | 26 ± 3             | <.001     |
| Baseline LVEF | 56% ± 6%        | 34% ± 3%           | <.001     |
| Baseline heart rate (bpm) | 66 ± 12    | 73 ± 16            | .03       |

Abbreviations: bpm, beats per minute; ECG, electrocardiogram; LVEF, left ventricular ejection fraction; SD, standard deviation.

*Values are presented as means ± SD unless otherwise specified.

**Table 2. Baseline ECG Abnormalities: Treated Cohort**

| Abnormality                             | Count |
|----------------------------------------|-------|
| Right bundle branch block (RBBB)       | 5     |
| Incomplete right bundle branch block   | 2     |
| Left bundle branch block               | 0     |
| Incomplete left bundle branch block    | 1     |
| Left anterior fascicular block         | 4     |
| Left posterior fascicular block        | 2     |
| Combined RBBB + hemiblock              | 3     |
| Frequent premature ventricular complex | 2     |
| Sinus bradycardia                      | 15    |
| Repolarization abnormalities           | 4     |

Abbreviations: ECG, electrocardiogram; RBBB, right bundle branch block.
to precede the development of Chagasic cardiomyopathy (CC) [10, 18, 21–23].

The protozoan *T. cruzi* likely causes both direct damage and reactive inflammation leading to myocardial fibrosis, systolic and diastolic dysfunction, scar-related ventricular arrhythmias, microvasculopathy, cellular damages, fibrosis of the conduction system, and autoimmunity [14, 24–26]. The point at which irreversible damage has occurred is still unclear. The largest randomized trial to date, the BENEFIT trial, showed that antitrypanosomal therapy with benznidazole for 60 days in CC did not significantly reverse myocardial damage to the point where either EF or major outcomes improved [9].

Our small study raises the possibility of extending those findings to patients with both normal EFs and ECG abnormalities, although a larger cohort should be studied to confirm these results. Chagas disease is associated with specific ECG patterns related to the pathological mechanism of disease. Prior studies have shown that certain findings, such as incomplete left bundle branch block, are no more prevalent in CD than in comparable patients with non-CD cardiomyopathy, but that, regardless of EF, the presence of RBBB, and in particular a combination of RBBB and LAFB, is strongly associated with the presence of CD [6, 15, 17]. In the BENEFIT trial, baseline ECG abnormalities were present in >90% of patients with CC, including >50% of patients with RBBB [9].

These ECG changes may hypothetically presage CC and signal a threshold of cardiac damage beyond which patients do not derive benefit from antitrypanosomal therapy, although prior research is conflicting. Among a cohort of 111 children with normal baseline ECGs treated with 5 mg/kg benznidazole per day for 60 days, 18.6% developed new ECG abnormalities over 8 years of follow-up; compared with untreated children with CD, there was no significant difference in the incidence of new ECG abnormalities [27]. These results contrast with our own, which suggest that there is a difference between treated patients with and without baseline ECG abnormalities; however, in the above-mentioned study, there was significant crossover from the untreated to the treated group during the assessment period, limiting the total number analyzed, and there was a limited ability to assess persistent parasitemia after treatment. Differences in the case definition of ECG abnormalities, with our definition including a narrower, more specific range of ECG findings, as well as age, duration of infection, and geographic differences may also explain these contrasting findings.

On the other hand, a smaller study of 43 CD patients treated with itraconazole in Chile revealed that 10.9% of patients with normal ECGs developed new ECG abnormalities over a 20-year period, compared with a historical rate of 9.7% per year in a separate cohort of untreated CD patients; and only 1 patient with an abnormal baseline ECG converted to a normal one over the 2 decades of follow-up [28]. A larger study of 310 treated and untreated CD patients with normal ECGs at baseline found a significant difference in the rate of new ECG changes over 20 years between untreated patients and those treated with benznidazole (53.19% vs 20.02%, *P* < .0001) [29]. Together with our research, these papers support consideration and further study of a strategy targeting early treatment before the development of cardiac disease as manifested by either baseline ECG changes or structural heart changes.

Our study has a number of limitations. Despite being the largest US cohort of treated CD patients, the sample size of treated patients (n = 59) is nonetheless too small to justify generalization, and these results should be considered preliminary and hypothesis-generating. This was an observational study,
Electrocardiogram Changes With Antitrypanosomal Treatment • OFID • 5

which is not adequate to measure pharmacological efficacy. Only a few covariates were available for analysis, which, along with the small sample size, limited our ability to control for confounding or perform multivariate analysis, and we did not have follow-up titer data with which to correlate our findings. In addition, there are limited ECG criteria for assessing the probability of CD-attributable ECG abnormalities, leading to possible misclassification. However, prior research suggests the number of ECG alterations correlates with elevation of N-terminal probrain natriuretic peptide (NT-proBNP) levels suggestive of heart failure [8]. Furthermore, CD is associated with particular ECG patterns, especially the combination of RBBB and IAFB. The prevalence of ECG alterations is much higher among individuals with CD than seronegative individuals, and within T cruzi-positive individuals, is associated with age and male gender [30]. The development of a range of ECG abnormalities, including RBBB, IAFB, and first-degree atrioventricular block, has been reported among CD patients with a normal baseline ECG [6, 15, 31].

CONCLUSIONS

In conclusion, in this small cohort study, the presence of significant baseline ECG abnormalities was associated with the development of further conduction system disease despite antitrypanosomal treatment, whereas no such abnormalities developed in patients with a normal ECG at baseline who underwent treatment. Future therapeutic trials in patients with normal systolic function should provide subgroup analyses based on baseline ECG findings.

Acknowledgment

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rev 2015; 90:33–43.
2. Manne-Goehler J, Umeb CA, Montgomery SP, Wirtz VJ. Estimating the burden of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation 2018; 138:e169–209.
3. Rojas LZ, Glisic M, Pletsch-Borba L, et al. Electrocardiographic abnormalities in Chagas disease: a systematic review and meta-analysis. PLoS Negl Trop Dis 2018; 12:e0006567.
4. Brito BO, Pinto-Filho MM, Cardoso CS, et al. Association between typical electrocardiographic abnormalities and NT-proBNP elevation in a large cohort of patients with Chagas disease from endemic area. J Electrocardiol 2018; 51:1039–43.
5. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015; 373:1295–306.
6. Viollet R, Vigiliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994; 127:151–62.
7. Brito BO, Pinto-Filho MM, Cardoso CS, et al. Association between typical electrocardiographic abnormalities and NT-proBNP elevation in a large cohort of patients with Chagas disease from endemic area. J Electrocardiol 2018; 51:1039–43.